Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

United Therapeutics

Pharmaceutical intelligence for United Therapeutics with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 3
Assets: 3

Recent signals(3)

ClinicalJuly 8, 2026

United Therapeutics' Ralinepag Shows Potential in Improving Exercise Capacity in PH Patients

The ADVANCE CAPACITY study evaluates ralinepag's impact on exercise capacity in patients with WHO Group 1 pulmonary hypertension.

ClinicalJune 17, 2026

Phase III Trial of Dinutuximab in High-Risk Neuroblastoma Shows Promise

A phase III trial is evaluating the efficacy of dinutuximab combined with standard chemotherapy and surgery for high-risk neuroblastoma in children.

RegulatoryJune 6, 2026

FDA Accepts Supplement Application for Tyvaso (Treprostinil)

The FDA has accepted a supplemental application for Tyvaso, an inhaled formulation of treprostinil.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(1)

RegulatoryJune 6, 2026

FDA Accepts Supplement Application for Tyvaso (Treprostinil)

The FDA has accepted a supplemental application for Tyvaso, an inhaled formulation of treprostinil.

Clinical activity(2)

ClinicalJuly 8, 2026

United Therapeutics' Ralinepag Shows Potential in Improving Exercise Capacity in PH Patients

The ADVANCE CAPACITY study evaluates ralinepag's impact on exercise capacity in patients with WHO Group 1 pulmonary hypertension.

ClinicalJune 17, 2026

Phase III Trial of Dinutuximab in High-Risk Neuroblastoma Shows Promise

A phase III trial is evaluating the efficacy of dinutuximab combined with standard chemotherapy and surgery for high-risk neuroblastoma in children.

Competitive activity

No signals indexed for this entity yet.

Assets

Dinutuximab →

Therapeutic areas

Neuroblastoma →

Oncology · Neuroblastoma →

Prostacyclin Analog →

Pulmonary Arterial Hypertension →

Pulmonary Arterial Hypertension · Prostacyclin Analog →

Pulmonary Hypertension →

Pulmonology →

Pulmonology · Pulmonary Hypertension →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.